Abstract
Screening of <i><scp>JAK</scp>2</i> V617F and <i>MPL</i> W515 K/L negative essential thrombocythaemia patients for mutations in <i><scp>SESN</scp>2, <scp>DNAJC</scp>17, <scp>ST</scp>13, <scp>TOP</scp>1<scp>MT</scp>,</i> and <i><scp>NTRK</scp>1</i>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
